Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
The new HA filler Evolysse uses a near-freezing cross-linking process the company says yields greater durability and required on average 20% less material in FDA studies, and the premium Evolysse product Sculpt is under FDA review with a targeted Q4 approval (excluded from 2026 revenue guidance). Jeuveau exited 2025 with 14% U.S. market share and Evolus is expanding a portfolio rebate program to deepen clinic share, while guiding 2026 operating expenses of $210–216M , low-to-mid single-digit adjusted EBITDA and a long-term revenue target of $450–500M by 2028 Interested in Evolus, Inc.? Here are five stocks we like better. Evolus (NASDAQ:EOLS) executives told investors at Needham & Company's 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as it expands beyond its flagship neurotoxin Jeuveau and scales its newer hyaluronic acid (HA) filler line, Evolysse. In a fireside chat moderated by Needham healt
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus to Report First Quarter Financial Results on May 4, 2026Business Wire
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]Yahoo! Finance
- Telix Appoints David Gill as Non-Executive Director [Yahoo! Finance]Yahoo! Finance
- Evolus to Participate in the Needham 25th Annual Virtual Healthcare ConferenceBusiness Wire
- Aviva Aesthetics Partners with Nationally Recognized Injector Jordan White and Urban Medical, Expanding into Arizona and VirginiaPR Web
EOLS
Earnings
- 3/3/26 - Beat
EOLS
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- EOLS's page on the SEC website